Medical Developments International Limited (MVP) AI Stock Analysis

• Market Cap: AU$80.55M
• Dividend Yield: N/A
• Average Volume (3M): 118.82K
• Price to Earnings (P/E): 715.0
• Beta (1Y): 1.27
• Revenue Growth: 17.82%
• EPS Growth: N/A
• Country: AU
• Employees: 68
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): >-0.01
• Shares Outstanding: 112,658,325
• 10 Day Avg. Volume: 79,692
• 30 Day Avg. Volume: 118,816
• PEG Ratio: -6.86
• Price to Book (P/B): 1.17
• Price to Sales (P/S): 1.65
• P/FCF Ratio: -132.97
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: AU$0.85
• Price Target Upside: 18.06% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 51 Neutral
• Price Target: AU$0.50 ▼(-30.56% Downside)

The overall stock score of 51 reflects significant challenges in financial performance, particularly in profitability and cash flow management. While technical analysis shows a positive price trend, the extremely high P/E ratio suggests overvaluation concerns. The absence of earnings call and corporate events data means these factors did not influence the score.

Medical Developments International Limited Business Overview & Revenue Model

Company Description

Medical Developments International Limited manufactures and distributes emergency medical solutions in Australia, Europe, the United States, and internationally. The company operates through Pain Management and Respiratory segments. It offers respiratory devices for sufferers of asthma and chronic obstructive pulmonary disease; Penthrox, a trauma and emergency pain relief product; and medical devices, such as CPR face shield key rings, CPR masks, finger pulse oximeters, flow meter regulators, MDI tourniquets, manually triggered ventilators, OXI port carry and hand bags, oxygen resuscitation kits, oxygen therapy masks, and resuscitators. The company was incorporated in 2003 and is headquartered in Scoresby, Australia.

How the Company Makes Money

Medical Developments International Limited generates revenue through the sale of its medical products across various markets. The primary revenue stream comes from the distribution of the Penthrox inhaler, which is in high demand in emergency medical settings due to its effectiveness and ease of use. The company also earns income from its respiratory and veterinary product lines, which are sold to healthcare facilities, clinics, and veterinary practices. MVP's earnings are further bolstered by strategic partnerships and distribution agreements that expand its market reach globally. The company may also engage in research and development collaborations, contributing to its revenue through the development of new and improved medical technologies.

Medical Developments International Limited Financial Statement Overview

Summary

Medical Developments International Limited exhibits a mixed financial performance. While there is some revenue growth and a strong gross profit margin, profitability remains a significant challenge. The balance sheet is stable with low leverage, but cash flow issues are a major concern, indicating potential liquidity risks. The company needs to focus on improving profitability and cash flow management to enhance its financial health.

Income Statement

The company has shown a modest revenue growth rate of 2.63% in the latest year, indicating some positive momentum. However, profitability remains a concern with a very low net profit margin of 0.24% and an EBIT margin of 0.36%. The gross profit margin is relatively strong at 75.35%, suggesting efficient production or service delivery. Overall, while there are signs of revenue growth, the company struggles with profitability.

Balance Sheet

The balance sheet is relatively strong with a low debt-to-equity ratio of 0.036, indicating low financial leverage and risk. The return on equity is minimal at 0.17%, reflecting challenges in generating returns for shareholders. The equity ratio is healthy, suggesting a stable financial structure. Overall, the balance sheet shows financial stability but limited profitability.

Cash Flow

The cash flow situation is concerning, with negative operating cash flow and free cash flow. The free cash flow growth rate is significantly negative at -92.85%, indicating deteriorating cash generation capabilities. The free cash flow to net income ratio is high at 11.30, suggesting that cash flow issues are not aligned with reported net income. Overall, the cash flow statement highlights significant challenges in cash generation and management.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	39.06M	39.06M	33.15M	32.34M	21.94M	25.27M
Gross Profit	29.43M	29.43M	24.37M	-2.52M	-3.06M	16.67M
EBITDA	1.67M	1.67M	-29.45M	-4.28M	-12.86M	-11.11M
Net Income	94.00K	94.00K	-40.99M	-5.61M	-12.41M	-12.56M
Balance Sheet
Total Assets	66.40M	66.40M	59.16M	109.49M	101.36M	100.17M
Cash, Cash Equivalents and Short-Term Investments	17.84M	17.84M	9.73M	24.66M	20.40M	36.28M
Total Debt	1.99M	1.99M	2.29M	2.56M	2.81M	3.05M
Total Liabilities	11.29M	11.29M	13.43M	28.17M	44.06M	31.87M
Stockholders Equity	55.10M	55.10M	45.73M	81.31M	57.30M	68.30M
Cash Flow
Free Cash Flow	-486.00K	-486.00K	-13.95M	-24.16M	-15.94M	-15.37M
Operating Cash Flow	-43.00K	-43.00K	-10.78M	-16.50M	-10.72M	-8.81M
Investing Cash Flow	-1.04M	-1.04M	-3.17M	-7.67M	-5.21M	-6.56M
Financing Cash Flow	8.68M	8.68M	-807.00K	28.06M	142.00K	36.12M

Medical Developments International Limited Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.72
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:MVP, the sentiment is Positive. The current price of 0.72 is above the 20-day moving average (MA) of 0.68, above the 50-day MA of 0.65, and above the 200-day MA of 0.61, indicating a bullish trend. The MACD of 0.02 indicates Negative momentum. The RSI at 57.72 is Neutral, neither overbought nor oversold. The STOCH value of 80.21 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:MVP.

Medical Developments International Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VIT	64 Neutral	AU$46.39M	12.96	7.64%	2.86%	0.13%	-12.90%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
MVP	51 Neutral	AU$80.55M	715.00	0.19%	―	17.82%	―
AGH	41 Neutral	AU$19.03M	―	-218.38%	―	-47.30%	82.53%
IDT	41 Neutral	AU$24.40M	―	-35.58%	―	45.30%	-24.18%
BOD	39 Underperform	AU$4.26M	16.00	―	―	69.59%	―

Medical Developments International Limited Corporate Events

Medical Developments International Achieves Positive Cash Flow and Expands Penthrox Market

Medical Developments International Limited reported a positive operating cash flow for the second half of FY25, with significant improvements in revenue and financial position. The company saw increased demand for Penthrox, particularly in Australian hospitals, and successfully transitioned its distribution in France and Switzerland to partners. Despite a slight decline in respiratory revenue due to seasonal factors, the overall financial performance was bolstered by higher pricing and volume growth. The company plans to continue investing in strategic initiatives to accelerate the adoption of Penthrox and improve operational efficiencies.

The most recent analyst rating on (AU:MVP) stock is a Hold with a A$0.71 price target. To see the full list of analyst forecasts on Medical Developments International Limited stock, see the AU:MVP Stock Forecast page.

Medical Developments International Issues New Performance Rights

Medical Developments International Limited announced the issuance of 2,687,635 performance rights under an employee incentive scheme. These securities are unquoted and subject to transfer restrictions, reflecting the company’s strategy to incentivize its workforce and align their interests with corporate performance, potentially impacting its operational efficiency and market positioning.

The most recent analyst rating on (AU:MVP) stock is a Buy with a A$0.80 price target. To see the full list of analyst forecasts on Medical Developments International Limited stock, see the AU:MVP Stock Forecast page.

Medical Developments International Appoints New Director to Drive Strategic Growth

Medical Developments International Limited announced the resignation of Richard Betts and the appointment of Paul Townsend to its Board, effective 30 May 2025. Paul Townsend, a seasoned finance leader with extensive experience across multiple sectors, will assume the role of Chair of the Audit & Risk Committee. His background in driving business outcomes and leading major organizational changes is expected to support MVP’s strategic growth objectives. The company anticipates that Townsend’s expertise will aid in unlocking its full potential and achieving long-term global growth.

The most recent analyst rating on (AU:MVP) stock is a Buy with a A$0.80 price target. To see the full list of analyst forecasts on Medical Developments International Limited stock, see the AU:MVP Stock Forecast page.